Xenomorph
  • Solutions
  • Technology
  • Customers
  • Resources
  • News
  • About Us
  • Request a Demo
  • Search
  • Menu Menu
  • Twitter
  • LinkedIn

News

Fight-back by the OTC Market?

An FT article I read earlier this week put me on to an interesting report on the OTC derivatives market commissioned by the City of London and written by a consultancy Bourse Consult. The report seems to be have been commissioned in defence of OTC industry against the predictable knee-jerk of regulatory proposals following the current financial crisis. Main points from the report are:

  • The OTC market is global and very large, much larger (by notional I guess) than either the exchange traded market or the cash markets
  • London accounts for 43% of the OTC market, with 24% in the US
  • It clarifies and emphasises that CDOs on ABS sold into off balance sheet special investment vehicles are where the main losses in the current crisis have been incurred
  • The CDS market and the OTC market in general did not cause the current crisis
  • Being seen to be "doing something" is driving much stricter regulation for CDSs and the whole of the OTC market, not just for the CDO products at the heart of the crisis 
  • Those arguing that OTCs must be traded on exchanges are mistaken since the OTC market and the exchanges are complimentary and need each other to thrive and develop new products
  • Many OTCs could by cleared centrally by a CCP without requiring listing on an exchange
  • However desirable, there are certain types of OTCs that are not suitable for a CCP
  • The current crisis was caused by mistakes by the ratings agencies, poor risk management by the banks and a lack of questioning of these participants by the regulators
  • Fundamentally this is a people-led not product-led crisis
  • Pressues to set up regional CCPs are mis-guided as the OTC market is a globally one and ultimately it will decide which CCPs succeed.

The report is well written and well worth a read. However, to suggest that the current financial crisis is purely people-led and that financial products are blameless is not completely the case in my view. I guess it depends upon your interpretation of whether regulation should directly limit the types of financial products created and their usage, or simply focus on regulating the people who are creating and using them. Given the current focus on getting CCPs set up for CDSs and other OTCs, it seems like governments and regulators are taking the approach of directly addressing perceived issues with financial products in addition to the more obvious (but more difficult?) people issues.

Also sounds like there is some work to be done in the EU, US and elsewhere if London is to remain the global centre of the OTC market – given the current performance of the UK Government this is not an encouraging prospect for London.

Share this entry
  • Share on Twitter
  • Share on LinkedIn
  • Share by Mail
https://www.xenomorph.com/wp-content/uploads/2019/07/logo-xeno.png 0 0 Brian Sentance https://www.xenomorph.com/wp-content/uploads/2019/07/logo-xeno.png Brian Sentance2009-05-01 10:09:332019-07-03 10:23:36Fight-back by the OTC Market?

Categories

  • Blog Post
  • Events
  • Press Release

Archives

About Xenomorph

Xenomorph provides trusted data management solutions to many of the world’s leading financial institutions.

With more than two decades’ experience managing large volumes of complex data and analytics we can quickly configure a solution for your requirements.

Xenomorph London

4th Floor
10 Lloyd’s Avenue
London EC3N 3AJ
UK

+44 (0)20 7614 8600

info@xenomorph.com

map

Xenomorph New York

45 Rockefeller Plaza, FL 20
New York
NY 10111
USA

+1-212-401-7894

info@xenomorph.com

map


Xenomorph Boston

53 State Street
Suite 500
Boston, MA 02109
USA

+1-617-465-2050

info@xenomorph.com

map

© Xenomorph Software Ltd 2022 - Privacy policy | Anti-Bribery Policy
Scroll to top
This website uses cookies to improve your experience. If you continue to use the site we will assume your consent. ACCEPTRead More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
SAVE & ACCEPT